Nortriptyline, a monoamine reuptake inhibitor, is a small molecule drug that exhibits its pharmacological action by targeting MATs. Eli Lilly, the pharmaceutical conglomerate, was the developer of this drug which, after a rigorous testing phase, received the green light for treating depressive disorder in November 1964. Nortriptyline belongs to the tricyclic antidepressant family and operates by bolstering the levels of neurotransmitters, such as serotonin and norepinephrine, within the brain. The drug performs its depression-fighting functions by inhibiting their reuptake, hence resulting in the alleviation of symptoms such as low mood, lack of energy and motivation, and disrupted sleep. Click on the image below to begin the exploration journey of Nortriptyline through the Synapse database!
You can search for the latest pharmaceutical information such as drugs, targets, patents, transactions, clinical results, etc. through the Synapse database. Come and experience it!